

**Government of the District of Columbia
Department of Health**

**Prescription Drug Monitoring Program
Advisory Committee Meeting**

**899 NORTH CAPITOL ST. NE – 2ND FLR.
WASHINGTON, DC 20002
WebEx VIRTUAL MEETING**

October 20, 2020

OPEN SESSION MEETING MINUTES

CALL TO ORDER:

PRESIDING:

COMMITTEE MEMBERSHIP/ATTENDANCE:

ADVISORY COMMITTEE MEMBERS:		
	Jacqueline Watson, DO, MBA, DC Health Chief of Staff	X
	Frank Meyers, JD, Board of Medicine Executive Director	X
	Shauna White, PharmD, RPh, MS, Board Of Pharmacy Executive Director	X
	Natalie Kirilichin, MD, MPH, Emergency Medicine Physician	X
	Sheri Doyle, MPH, Consumer Member	X
	Commander John Haines, Metropolitan Police Department	X
	Lakisha Stiles, CPhT – Pharmacy Technician	X
PDMP STAFF:	Justin Ortique, PharmD, RPh, Supervisory Pharmacist	X
	Brittany Allen, MPH, Program Specialist	X
	Cathryn Mudrick, MPH, Public Health Analyst	X
	Erica Loadman, PharmD, RPh, Pharmacist	X
LEGAL STAFF:	Carla Williams, Esq, Assistant General Counsel, PDMP Attorney Advisor	X
VISITORS:	Javon Oliver, DC Department of Behavioral Health	X
	Lammi Asrat, Pharmacy Intern, DC Health	X
	Ryan Bramble, Executive Director, DC CRISP	X
	Erika Hess, DC CRISP	X

Open Session Agenda

Quorum: Yes

1020-O-01	<p><u>Welcome & Introductions</u></p> <p>Dr. Jacqueline Watson opened the meeting with a roll call of the committee, staff, and visitors. Dr. Watson noted the charge of the committee, and stated the importance of moving forward with the work that has been done. She thanked the committee and staff for their efforts in moving the Prescription Drug Monitoring Program forward in the District. She noted that the 2019 annual report has been approved by Dr. Nesbitt and has been published to the DC Health website.</p> <p><u>Chair Report</u></p> <p><u>Charge of the Committee</u></p> <p>The Committee shall convene at least two (2) times per year to advise the Director:</p> <ul style="list-style-type: none">(a) On the implementation and evaluation of the Program;(b) On the establishment of criteria for indicators of possible misuse or abuse of covered substances;(c) On standardization of the methodology that should be used for analysis and interpretation of prescription monitoring data;(d) In determining the most efficient and effective manner in which to disclose the findings to proactively inform prescribers regarding the indications of possible abuse or misuse of covered substances;(e) On identifying drugs of concern that demonstrate a potential for abuse and that should be monitored; and(f) Regarding the design and implementation of educational courses for:<ul style="list-style-type: none">(1) Persons who are authorized to access the prescription monitoring information;(2) Persons who are authorized to access the prescription monitoring information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled substances or drugs monitored by the Program;(3) Prescribers on prescribing practices, pharmacology, and identifying, treating, and referring patients addicted to or abusing controlled substances or drugs monitored by the Program; and	
-----------	---	--

	(4) The public about the use, diversion and abuse of, addiction to, and treatment for the addiction to controlled substances or drugs monitored by the Program.	
1020-O-02	<p><u>Approval of July 2020 PDMP Advisory Committee Meeting Minutes</u></p> <p>(a) Minutes from July 21, 2020 Meeting</p> <p>Motion to approve July 2020 meeting minutes by: Frank Meyers</p> <p>Seconded by: Commander John Haines.</p> <p>(Roll call vote)</p> <p>Mr. Frank Meyers: Yes Dr. Natalie Kirilichin: Yes Commander John Haines: Yes Ms. Lakisha Stiles: Yes Ms. Sheri Doyle: Not yet present</p> <p>All in favor</p> <p>Motion carries, Minutes approved.</p>	
1020-O-03	<p><u>Report from Attorney Advisor</u></p> <p>(a) PDMP Legislative Update</p> <p>(1) Mandatory Query Legislation Update</p> <p>Ms. Carla Williams provided the legislative update, noting that Mandatory Query legislation has moved forward and is pending DC Council hearing. The committee will be updated in January if the law is passed.</p> <p>(2) Committee on Health Legislative Hearing Bill B23-0890 PDMP Mandatory Query October 28, 2020 4:00 p.m. to 6:00 p.m. Via WebEx</p>	
1020-O-04	<p><u>Presentation</u></p> <p><i>DC PDMP Update</i></p> <p><i>The impact of Covid-19 on opioid use</i></p> <p><i>42 Code of Regulations (CFR) update</i></p> <p>Erica Loadman, PharmD, RPh</p> <p>Pharmacist, DC Health, Health Regulation and Licensing Administration</p> <p>Dr. Erica Loadman gave a presentation on the impact of Covid-19 on opioid overdose rates, recent Overdose Data Mapping Application Program (ODMAP) data, and updates to 42 Code of Federal Regulations (CFR).</p> <p>Dr. Loadman noted that according to the National Institute for Drug Abuse (NIDA), the opioid crisis and the Covid-19 pandemic have the potential to exacerbate each other. She added that due to Covid-19, many people with Opioid Use Disorder (OUD) may face challenges such as less emotional support, disruption or changes in the drug supply, and financial struggles. She stated that the American Medical Association urges states to allow for use of telemedicine in treatment of Substance Use Disorder (SUD), remove administrative barriers for</p>	

	<p>SUD medications, remove administrative barriers for pain medications, and utilize harm reduction strategies.</p> <p>Citing a publication from Overdose Data Mapping Application Program (ODMAP) Dr. Loadman noted that in 2 out of 6 states assessed, there was a statistically significant positive relationship between the number of Covid-19 cases and the number of drug overdose deaths. She stated that people suffering from SUD are more vulnerable during the Covid-19 pandemic due to stigma, discrimination, poor health knowledge, substance use taking priority over overall health, and difficulty accessing harm reduction services. The ODMAP publication advises communities to implement new strategies for harm reduction, which include on-demand services, teleconferencing, alternative check-in methods, and alternative dosage forms (or additional take away dosages).</p> <p>Dr. Loadman provided an update to 42 Code of Federal Regulations. The most notable change was the following:</p> <ul style="list-style-type: none"> • Any part 2 program is now allowed (with proper written patient consent) to report SUD medication prescribed or dispensed to state PDMP if required by state law <p>During the discussion following the presentation, Mr. Javon Oliver noted that SAMHSA has been pushing 42 CFR to align more with HIPAA treatment and asked if the update had been finalized as of July 15, 2020. Dr. Loadman confirmed that yes, the update has been finalized.</p> <p>Mr. Oliver asked if DC Health has worked with the committee to refine how things are shared through the PDMP and noted that he chaired the committee while at DC Department of Health Care Finance (DCHF) and would be willing to connect DC Health staff to the committee.</p> <p>Dr. Watson added that there are a number of committees which sometimes overlap in efforts and we need to leverage resources to make an impact in a particular area. She stated that DC Department of Behavioral Health and DC Health have a collaborative committee that routinely meets and added that DCHF can join the effort in shaping policies and procedures that need to be put in place.</p>	
<p>1020-O-05</p>	<p>Report <i>Prescription Opioid Related Overdose Deaths Report – Prepared by OCME</i> Cathryn Mudrick, MPH Public Health Analyst, DC Health, Health Regulation and Licensing Administration</p> <p>Ms. Cathryn Mudrick gave a report on prescription opioid fatal overdoses in the District from January 1, 2019 to June 30, 2020, involving codeine, oxycodone, hydrocodone, hydromorphone, buprenorphine, and methadone.</p> <p>Ms. Mudrick noted that there were 40 fatal overdoses in 2019 and 26 from January – June 2020, which means that there will likely be an increase in total deaths in 2020. She noted that codeine has already surpassed 2019 data as a</p>	

	<p>contributing cause of death and methadone is slated to surpass 2019 data as a contributing cause of death in 2020. She noted that there may be a slight decrease in deaths attributable to oxycodone and potentially buprenorphine.</p> <p>Ms. Mudrick stated that there will likely be an increase in deaths among the 30-39 age group and the 60-69 age group in 2020, as well as an increase among African American males in wards 7 and 8, and potentially in ward 1. She also noted that there has been a slight increase in prescription opioid related fatalities among females. She concluded the presentation by stating that there may be some delayed reporting in Wards 3 and 5.</p> <p>During the discussion, Mr. Frank Meyers noted that this is the second or third report that has focused on methadone and asked if other drugs are factored into this data. Ms. Mudrick noted that fentanyl is a factor in other deaths, but this report focuses on prescription opioid fatality data.</p> <p>Dr. Watson asked Commander Haines to discuss the trends that Metropolitan Police Department (MPD) has seen recently. Commander Haines noted that fentanyl is currently the big thing. He added that counterfeit prescription pills containing pure fentanyl are being sold as real pills, because it's cheaper and more potent than heroin and there is a higher profit margin. He also stated that there have been more overdoses due to pandemic, but not necessarily more drug seizures and arrests, noting that the narcotics units are focusing more on long term issues, such as supply, rather than street sales.</p> <p>Dr. Watson noted that as we look back at 2020, we will need to look at data with a definitive lense and we need to be careful when labeling issues as covid-related, since there have been so many changes made to accommodate the pandemic.</p> <p>Mr. Meyers noted that he would like to determine if there is a secondary cause of death in the methadone cases and Ms. Mudrick stated that PDMP staff can follow up with OCME.</p>	
<p>1020-O-06</p>	<p><u>Discussion</u> B23-0535, Opioid Labeling Amendment Act of 2020</p> <p>Dr. Shauna White presented the Opioid Labeling Amendment Act of 2020, which requires specific labeling for opioid prescriptions that are dispensed in DC pharmacies. If a medication is derived from opium, a label is required to be affixed to the prescription given to the patient stating that it contains an opioid an can cause dependence and addiction. The act was reviewed during the Committee on Health (COH) Committee Mark-Up on October 7, 2020. DC Board of Pharmacy members and DC Health will provide more input on the bill.</p> <p>Mr. Oliver asked if methadone assisted therapy (MAT) providers are required to check the PDMP before continuing individuals on their maintenance dose of methadone, and Dr. White noted that DBH is welcome to provide testimony in support of mandatory query. Dr. Watson noted that testimony from other agencies and community members is helpful when presenting new legislation to the council.</p>	

<p>1020-O-07</p>	<p><u>Presentation</u> <i>DC PDMP Satisfaction survey results</i> Brittany Allen, MPH Program Specialist, DC Health, Health Regulation and Licensing Administration</p> <p>Ms. Brittany Allen gave a presentation on the DC PDMP user satisfaction survey. The survey, created utilizing Survey Monkey, was emailed to users via PMP Announcements, and received 475 responses. S</p> <p>During the discussion, Dr. Watson noted that a number of people chose “Not Applicable,” stating that they do not utilize the PDMP, or that they have not taken any action since registering with the PDMP. Ms. Allen noted that those respondents likely do not prescribe or dispense controlled substances.</p> <p>Mr. Oliver asked if practitioners are required to act in a certain way after querying the PDMP. Ms. Williams noted that practitioners are not required to reduce their prescribing and stated that the advisory committee can identify practices that may help prescribers compare their response to their peers, which may help drive behaviors. Dr. Watson noted that there are standards of care that practitioners follow regarding tapering and providing the best clinical experience for their patients. Mr. Meyers noted that providers should follow standards of care and the licensing boards may choose to take action if a practitioner is not adhering to standards of care. Dr. Kirilichin noted that standard of care is variable and when discussing tapering, it may be helpful to involve an addiction specialist in the discussion. Ms. Williams reviewed the committee’s duty and noted that the advisory committee can inform and advise, but from a regulatory perspective, the committee is not dictating or telling prescribers how to prescribe. Dr. Watson agreed, noting that DC Health is a regulatory agency and also wears a hat of convening and collaborating with other agencies to help inform and educate stakeholders.</p>	
<p>1020-O-08</p>	<p><u>Program Updates</u></p> <p>(a) PDMP Registration Statistics and Audit</p> <p>Dr. White shared updated user statistics, noting that within the past few weeks, more than 500 practitioners have registered for the DC PDMP, due to a mass email sent out by PDMP staff as well as collaboration with the DC Board of Nursing and the DC Board of Medicine to ensure licensees are registered for the PDMP before renewing their controlled substance registration.</p> <p>(b) Outreach Activities</p> <p>Past</p> <p>Future</p> <p>Dr. White shared that outreach will continue as mentioned during the best practice checklist discussion. Dr. Watson recommended collaborating with medical schools to conduct outreach with medical training programs.</p> <p>(c) PDMP Annual Report</p> <p>Dr. White shared that the annual report has been posted to the website.</p> <p>(d) CRISP Integration</p> <p>Mr. Ryan Bramble provided a brief CRISP update, noting that technical work is</p>	

	<p>complete to allow CRISP to integrate with APPRISS. Mr. Bramble stated that the program is being piloted now with participating health care practitioners. Mr. Bramble provided screenshots of CRISP in a web portal and CRISP in an embedded app, which would be integrated into a facility's electronic health record (EHR). Mr. Bramble shared that his team is working with Dr. White's team to develop specific messaging for users. Mr. Bramble noted that the pilot testing should be complete within 3-4 weeks and the program will likely be to scale by the end of the calendar year and before mandatory query legislation is passed.</p>	
<p>1020-O-09</p>	<p><u>Grant Updates</u></p> <ul style="list-style-type: none"> (a) Districtwide Gateway Integration 3 integrations added since July 2020 Current total: 24 (b) NarxCare Package (c) Opioid Communications Campaign (d) Pocket guide 	
<p>1020-O-10</p>	<p><u>PDMP Best Practice Checklist Updates and Discussion</u></p> <p>Dr. Shauna White provided an update of recent best practice checklist activities:</p> <ul style="list-style-type: none"> • Disseminate prescriber report cards quarterly <ul style="list-style-type: none"> ○ Most recent report was released September 2020 • Create online user guides and educational materials <ul style="list-style-type: none"> ○ FAQs updated (September 2020) ○ Pocket guides created (September 2020) • Conduct presentations and trainings for end-user groups <ul style="list-style-type: none"> ○ Howard University College of Pharmacy presentation (September 2020) ○ DHCF Pharmacy Provider Forum (September 2020, 2 sessions) • Proactive identification and outreach to enroll high impact users, e.g., top prescribers <ul style="list-style-type: none"> ○ Email sent to all active prescribers who had not registered for the DC PDMP (September 2020) • Mandate PDMP utilization (query) for prescribers and dispensers <ul style="list-style-type: none"> ○ Legislation in process • Send PDMP notification letters to new prescribers <ul style="list-style-type: none"> ○ Most recent email was sent October 2020 • Distribute reports <ul style="list-style-type: none"> ○ 2019 Annual Report is complete (has been posted to DC Health website) • Conduct satisfaction and utilization surveys of end-users <ul style="list-style-type: none"> ○ Disseminated via Survey Monkey September 2020 • Conduct audits of PDMP system utilization for appropriateness and extent of use • Promote visibility of PDMP via annual reports and news releases impact to motivate funding, etc. <ul style="list-style-type: none"> ○ In process of planning communications campaign with Engage Strategies, LLC (landing page will include link to PDMP website) 	

	<p>Dr. White shared that future activities include:</p> <ul style="list-style-type: none"> • Increase delegate registration (collaboration with DC Primary Care Association) • Utilize user survey feedback to create educational activities such as webinars and presentations • Reminding practitioners of resources available on the PDMP website • Increase EHR and pharmacy dispensing system integrations <p>Dr. Watson reinforced the importance of continuing outreach and recommended collaborating with DC Hospital Association. She stated that at some point soon, the PDMP advisory committee should begin developing an education and outreach strategy and thinking about including new partners and ways to engage them and encourage them to become ambassadors.</p> <p>Dr. Watson opened the floor for advice and guidance from committee members. Ms. Sheri Doyle commended the PDMP staff for their hard work and stated that continuing delegate outreach will go a long way and to keep up the good work.</p>	
<p>1020-O-11</p> <p>Matters for Consideration</p>	<p><u>Action Items</u></p> <ul style="list-style-type: none"> • Potential Future meeting dates FY-2021: <ul style="list-style-type: none"> ○ January 19, 2021 ○ April 20, 2021 ○ July 20, 2021 	
<p>1020-O-12</p>	<p>Other news/highlights from Committee members</p> <p>Upcoming Committee on Health Hearings:</p> <p><u>October 28, 2020 – COH Public Oversight Hearing, 9:00 a.m. to 4:00 p.m. - Webex</u> This hearing will examine the public health element of the District’s COVID-19 response:</p> <ul style="list-style-type: none"> • Deputy Mayor for Health and Human Services • Department of Health Care Finance • Department of Health <p><u>October 28, 2020 – COH Legislative Hearing, 4:00 p.m. to 6:00 p.m. - Webex</u></p> <ul style="list-style-type: none"> • B23-0890, Prescription Drug Monitoring Program Query Amendment Act of 2020 <p>Past hearings:</p> <p><u>October 7, 2020 – COH Committee Mark-Up, 11:00 a.m. to 12:00 p.m. – Webex</u></p> <ul style="list-style-type: none"> • B23-0535, Opioid Labeling Amendment Act of 2020 	
<p>Comments from the Public</p>	<p>None</p>	

Motion to Adjourn the Open Session	<p>Madam Chair, I move that the Committee close the meeting. Motion to adjourn by: Frank Meyers Seconded by: Dr. Shauna White (Roll Call Vote) Mr. Meyers: Yes Dr. White: Yes Dr. Kirilichin: Yes Ms. Stiles: Yes Ms. Doyle: Yes All in favor Motion carries. Meeting is adjourned.</p>	
---	--	--

This concludes the meeting.
Meeting Adjourned at 11:50AM